Financial Data and Key Metrics Changes - For Q3 2025, the company generated total revenue of $2.8 million, with $2.3 million from net product sales of ZUNVEYL and $507,000 from licensing revenue [11] - Total operating expenses were $8.2 million, including $633,000 in cost of goods sold, reflecting an increase from $2.5 million in operating expenses in Q3 2024 [11] - The net loss was reported at $1.3 million, or $0.08 basic loss per share, an improvement from a net loss of $1.9 million, or $0.31 per share, in the previous year [12] Business Line Data and Key Metrics Changes - ZUNVEYL sales showed significant growth, with ex-factory purchases rising 44% from Q2 to Q3, and demand sales bottles dispensed growing 102% [15] - The company engaged with 2,038 homes in Q3, with 605 homes ordering ZUNVEYL, and 70% of those homes placing repeat orders [16] Market Data and Key Metrics Changes - The company anticipates continued sequential growth in ZUNVEYL's sales as awareness and payer access expand through 2026 [13] - The average of 16 years of industry experience among sales representatives is driving clinical education and adoption across the long-term care market [18] Company Strategy and Development Direction - The company plans to invest in sales, marketing, and research for ZUNVEYL, particularly focusing on behavioral symptoms associated with Alzheimer's [5] - The company is also advancing its sublingual formulation and anticipates running a comparative PK study in Q1 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ZUNVEYL's potential, highlighting the drug's clinically meaningful benefits across cognitive and behavioral symptoms [10] - The company remains focused on executing its commercial strategy and maintaining financial discipline to create long-term value for shareholders [14] Other Important Information - The company raised approximately $38 million in net proceeds through an equity offering in October, strengthening its balance sheet [12] - The company expects to initiate two studies in long-term care settings in Q4 2025 and Q1 2026 to assess ZUNVEYL's cognitive benefits and tolerability [9] Q&A Session Summary Question: Current status of contracting discussions and GPO agreements for ZUNVEYL - The company has one contract with a major PBM and is close to finalizing another by the end of the quarter, targeting four key Medicare plans [23][24] Question: Coverage without restrictions - Currently, about 15% of the signed plan has adopted ZUNVEYL without restrictions, with more visibility expected in the coming quarters [25] Question: Breakdown of unique prescribers and repeat orders - In Q3, 576 prescribers wrote orders, with 62% writing multiple orders, and 70% of homes placing repeat orders [27][28] Question: Key marketing messages resonating with prescribers - The most impactful messages include ZUNVEYL's effect on behaviors and its lack of impact on sleep, which is a significant concern for prescribers [31][32] Question: Sales cycle and prescriber interactions - The sales cycle remains initially slow, but once prescribers gain confidence, they tend to increase their patient base more rapidly [41]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $3.5 million, reflecting a 19% increase compared to Q3 2024, driven by an increase in the number of CapsoCam Plus capsules sold [15] - Gross margin was 54% for the quarter, consistent with expectations as the company scales [15] - Net loss for Q3 2025 was $7.9 million, compared to a net loss of $5.8 million in Q3 2024 [16] - Cash and equivalents at the end of the quarter were $17.8 million, an increase from $1.1 million at June 30, 2025, following the completion of the IPO [16] Business Line Data and Key Metrics Changes - CapsoCam Plus has been used by over 151,000 patients, with approximately 8,336 patients using the system in Q3 2025, representing a 20% year-over-year growth [11] - New account generation grew by 31% in Q3 2025 compared to the same quarter in 2024, indicating strong physician adoption [14] - A 24% increase in GI clinics and mega GI groups was noted in Q3 2025 over the same quarter last year [14] Market Data and Key Metrics Changes - The company is gaining traction in hospitals and GPOs, with a 26% increase in hospital system customers over the prior year [14] - The U.S. direct sales team included 26 representatives, supported by seven regional sales managers and trainers as of September 30, 2025 [12] Company Strategy and Development Direction - The long-term vision is to deliver an ingestible capsule that can screen for multiple cancers in a single non-invasive procedure powered by advanced imaging and AI [4] - The company is investing in AI to improve existing products and plans to submit an application to the FDA by year-end 2025 for AI technology incorporation into CapsoCam Plus [5][6] - CapsoVision is pursuing Breakthrough Device Designation for its non-invasive capsule endoscopy system to enable earlier detection of pancreatic ductal adenocarcinoma [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum across the business, highlighting commercial growth, pipeline expansion, and advancements in AI-assisted diagnostics [18] - The application for Breakthrough Device Designation reflects the urgent need for early detection of pancreatic cancer and the promise of the company's technology [18] - The company is strengthening its leadership team and executing a clear growth plan following a successful IPO [19] Other Important Information - The company has a development agreement with Canon Incorporated to design next-generation CMOS imaging sensors, marking a key step in advancing its innovation pipeline [16] - R&D expenses related to the Canon agreement were $1.6 million for Q3 2025, considered a one-time charge [15] Q&A Session Summary Question: Impact of AI feature submission on other milestones - Management indicated that the FDA review typically takes three to six months, so the approval should be available in the second half of the year [22] Question: Operating expenses related to Canon agreement - The $1.6 million expense for R&D for Canon is a one-time charge, and future core R&D expenses should be lower [23] Question: Clinical data for breakthrough designation application - A small feasibility study conducted six years ago showed promising results, with two out of 20 subjects diagnosed with cancer [28] Question: Timeline for Canon CMOS sensor - The pivotal study for pancreatic cancer will proceed without waiting for the Canon sensor, which is expected to be ready in 2026 [35] Question: Commercial organization headcount - The current sales team will be maintained, with plans to add two additional territories in 2026 as needed [36]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $11.6 million, representing a 57% increase year-over-year and a 3% sequential gain over Q2 2025 [5][16] - Gross margin for the quarter was 84%, down from 86% in the prior year, primarily due to lower manufacturing efficiency associated with newly launched products [17] - Operating loss for the quarter was $9 million, compared to $8.7 million in the prior year, driven by one-time charges related to clinical studies [18] - Cash used in operations was $3.7 million, a significant improvement from $11.2 million in Q3 2024 [19] - Adjusted EBITDA loss improved to $5.4 million from $7.1 million in the prior year [19] Business Line Data and Key Metrics Changes - The commercial organization increased the number of unique ordering accounts by 30% compared to Q3 2024, adding 20 new accounts [16] - The reimbursement use of TriNav technology within the radioembolization market has effectively doubled due to the introduction of a new CMS code [6][7] - The company launched the TriNav Flex infusion system and advanced new clinical applications to expand market opportunities [5][6] Market Data and Key Metrics Changes - The company is experiencing strong commercial momentum in the complex liver embolization market, supported by the new CMS HCPCS code C8004 [6][7] - Early feedback from key accounts indicates strong clinical and economic advantages from the expanded reimbursement, expected to drive adoption into 2026 [7] Company Strategy and Development Direction - The company is focused on expanding its TriNav platform and investing in long-term growth through increased commercial resources and funding for new applications [6][8] - Trisalus aims to leverage its pressure-enabled drug delivery (PEDD) technology across a wide range of solid tumors and interventional treatment approaches [8][15] - The company is also preparing to launch a clinical trial evaluating TriNav and genicular artery embolization (GAE) for knee osteoarthritis [12][43] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed a 50% revenue growth guidance, reflecting confidence in growth momentum and market opportunities [7][21] - The company is excited about the current momentum, especially in Q4, and is focused on maintaining its growth trajectory [21][27] - Management highlighted the potential of GAE as a significant market opportunity, potentially rivaling the liver market [42][43] Other Important Information - The company simplified its capital structure through a successful exchange offer and consent solicitation for preferred stock [6] - Cash and cash equivalents at the end of the quarter were $22.7 million, providing ample liquidity for operations and strategic objectives [19] Q&A Session Summary Question: Insights on 2026 growth expectations - Management is confident about current momentum and maintaining guidance of 50% growth and adjusted EBITDA positivity in the first half of next year [21] Question: Growth in other indications outside liver - The company is investing in new applications, particularly in uterine artery embolization, which is expected to reduce procedural time and pain [22] Question: Gross margin outlook - Management expects an uptick in gross margins in Q4 as manufacturing efficiencies improve [33] Question: Adoption of new products - The TriNav Flex has been well received, with significant adoption in selective treatments and larger territory treatments [38] Question: Utilization trends for accounts launched at different times - Accounts launched 18 months ago continue to improve month over month, with faster ramps for those familiar with the technology [44]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company reported cash and cash equivalents of $8.3 million, which does not include a recent $2 million milestone payment received in October 2025 [12] - The net loss for the third quarter of 2025 was $15.8 million, an increase from a net loss of $10.6 million in the same quarter of 2024, primarily due to the absence of collaboration revenue recorded in 2024 [12][13] - Research and development (R&D) expenses decreased to $9.5 million in Q3 2025 from $16.4 million in Q3 2024, driven by reduced program development costs and lower headcount-related expenses [13] - General and administrative (G&A) expenses were $4.2 million for Q3 2025, down from $5.9 million in Q3 2024, attributed to reduced personnel costs [14] Business Line Data and Key Metrics Changes - The company is preparing to initiate a phase 3 study for OSV, which has shown promising clinical activity in heavily pretreated patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) [5][7] - The dual CAB, EpCAM, T-cell engager program is progressing well, with preliminary data indicating a manageable safety profile and encouraging signs of tumor reductions across various indications [10] Market Data and Key Metrics Changes - The worldwide peak sales estimate for OSV in second-line and later OPSCC is approximately $800 million, with the total worldwide OPSCC market projected to reach $3 billion by 2032 [7] - The broader HPV-positive solid tumor market, including cervical cancer, is valued at over $7 billion globally [8] Company Strategy and Development Direction - The company is in advanced stages to finalize a strategic transaction with a potential partner by year-end, indicating a focus on collaboration and partnerships [4][5] - The company aims to address critical unmet needs in oncology through its prioritized programs, particularly the dual CAB, EpCAM, TCE program, which has the potential to treat over 1 million adenocarcinoma cancer patients annually [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming phase 3 trial for OPSCC, which addresses a significant unmet need and represents a substantial commercial opportunity [15] - The company anticipates key clinical trial readouts in the first half of next year, with several important events related to its programs throughout 2026 [15] Other Important Information - The company achieved FDA alignment on the phase 3 OSV registrational trial design, which includes dual primary endpoints of overall response rate and overall survival [4][5] - A development milestone was achieved under the license agreement with Context Therapeutics, validating the T-cell engager platform [5] Q&A Session Summary Question: Can you provide details on the patient number for the ROR-2 program's phase 3 study and control arm stratification? - The pivotal trial design for full approval involves approximately 300 patients, with an interim analysis for accelerated approval occurring earlier [18][19] Question: What data can be expected from the 3182 program next year? - The next data output is anticipated in the first half of next year, with comprehensive reporting on additional dose and schedule evaluations [21][22]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $142 million, a decrease of 15% compared to $166 million in Q3 2024, primarily due to a one-time favorable claim settlement contributing $31 million in the prior year [16][17] - Adjusted EBITDA for Q3 2025 was $4 million, down from $30 million in Q3 2024, influenced by the one-time GGB project settlement [20] - The company reported a net loss of $4 million for Q3 2025, compared to a net loss of $2 million in Q3 2024 [20] Business Line Data and Key Metrics Changes - Revenue from Shimmick projects was $107 million, a 5% increase year-over-year, while non-core project revenue was $35 million, a decrease of 46% [17][19] - Gross margin for Shimmick projects was $10 million, up 61% compared to $6 million in Q3 2024, while gross margin for non-core projects was $1 million, down from $6 million [18][19] Market Data and Key Metrics Changes - The company achieved $1 billion in bidding volumes in September and October, indicating a robust pipeline [8] - The backlog grew by over $100 million, or 15% sequentially, reaching $754 million as of October 3, 2025 [12][21] Company Strategy and Development Direction - The company's strategy focuses on growing the top line through strategic new business, completing non-core projects, and implementing operational improvements [4][5] - The company aims to increase the percentage of negotiated work in its backlog to 50% by 2027, balancing risk and revenue generation [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory, citing strong market conditions and backlog growth as key drivers for future performance [14] - The company anticipates that the completion of non-core projects will positively impact cash flow and overall financial health by 2026 [30] Other Important Information - The company maintained a strong liquidity position with total liquidity of $48 million at the end of Q3 2025 [21] - The company reaffirmed its full-year 2025 guidance, expecting Shimmick project revenue in the range of $405 to $415 million [23] Q&A Session Summary Question: Can you discuss the growth of Axia and its representation in the backlog? - Management indicated that Axia currently represents about 15-16% of the backlog, with growth expected in electrification-related work and industrial electrical projects [27][28] Question: What is the status of data center projects and their market activity? - Management noted active bidding in Texas and other regions, with a significant demand for data center projects [29] Question: Can you elaborate on cash flow dynamics and future trends? - Management acknowledged the negative impact from non-core legacy projects but expects improved cash flow as backlog increases and translates into revenue [30][31] Question: What gives confidence for a strong fourth quarter? - Management attributed confidence to new higher-margin work starting to kick in, offsetting lower-margin non-core projects [34][35] Question: How is the transition to more negotiated work progressing? - Management reported that negotiated work is becoming a larger portion of bidding activity, with a goal of achieving a 50% mix in the future [36][38]

Financial Data and Key Metrics Changes - The company's Q3 2025 revenue was $1.2 million, down 16% year-over-year due to decreased sales of M400 smart glasses [18] - Engineering services revenues were $0.3 million, down from $0.4 million in the prior year's period [18] - The net loss for Q3 2025 was $7.4 million or $0.09 per share, compared to a net loss of $9.2 million or $0.14 per share for the same period in 2024 [21] - Cash and cash equivalents as of September 30, 2025, were $22.6 million, up from $17.5 million as of June 30, 2025 [21] - Total operating expenses for Q3 2025 declined by $1.8 million or 20% to $7.1 million compared to $9 million in the prior year [20] Business Line Data and Key Metrics Changes - The OEM and defense business is accelerating, with revenue contributions expected to begin in Q4 2025 from military applications [8] - The enterprise segment, which currently accounts for the majority of revenue, is seeing increased interest in AI-enabled smart glasses [9] - The company is transitioning into production deliveries for military applications, with a six-figure development order expected to be delivered in Q4 [8] Market Data and Key Metrics Changes - Demand for high-quality color waveguides is rising, with Vuzix positioned to serve this market [7] - The company has signed NDAs with multiple ODMs and micro-display makers, indicating strong market interest [6] Company Strategy and Development Direction - Vuzix is focusing on ramping production capacity in collaboration with Quanta Computer, aiming for significant volume increases in the future [5][26] - The company is developing advanced high-index materials for waveguides to meet future performance requirements [10] - The introduction of the LX1 smart glasses is part of a strategy to expand the product portfolio and cater to different customer needs [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the increasing momentum in business and revenue for Q4 2025 [9] - The company is focused on maintaining a disciplined cost structure and converting inventories into cash to support operations through 2026 [22] - Management noted that the Amazon program is expanding significantly, indicating strong potential for future revenue growth [34] Other Important Information - The company has welcomed Dr. Chris Parkinson as President of Enterprise Solutions, aiming to enhance the enterprise sales strategy [10] - The company has no current or long-term debt obligations outstanding, providing a strong financial position [21] Q&A Session Summary Question: Discussion on Quanta's capacity ramp - Management confirmed ongoing discussions with Quanta to increase production capacity beyond the current one million waveguides per year, with potential for millions as the market grows [26] Question: Timeline for capacity ramp discussions - Management indicated that while discussions are ongoing, it may take time to establish new production lines, with updates expected in the coming quarters [27] Question: Clarity on defense industry volume ramp - Management stated that production waveguides are being shipped in Q4, with expectations for increased revenue from OEM business [28] Question: Expansion of defense contractor customer base - Management anticipates rapid development and production ramp-up for existing programs, with potential for additional contracts in 2026 [29] Question: Update on the Amazon program - Management highlighted the successful rollout of Vuzix glasses in Amazon's operations, with plans for further expansion into new applications [34] Question: Gross margins outlook - Management noted that new products like the LX1 have better margin models, and higher margins are expected in 2026 as the product mix improves [36]

Financial Data and Key Metrics Changes - Rekor Systems reported record revenue of $14.2 million for Q3 2025, a 35% increase compared to Q3 2024 and a 15% increase compared to Q2 2025 [6] - Year-to-date revenue reached $35.8 million, up 9% from the first nine months of 2024 [6] - Adjusted gross margin improved to 63% in Q3 2025 from 44% in Q3 2024, and year-to-date adjusted gross margin was 55% compared to 48% in the prior year [7][8] - Adjusted EBITDA loss for Q3 2025 was $1.5 million, an improvement of $7.9 million or 84% from Q3 2024 [8][9] Business Line Data and Key Metrics Changes - Recurring revenue for Q3 2025 totaled $6.5 million, an 18% increase compared to Q3 2024, while year-to-date recurring revenue was $17.5 million, up 5% year over year [7] - The company continues to focus on expanding its recurring revenue base through long-term software and data-as-a-service subscription contracts [7] Market Data and Key Metrics Changes - Rekor secured a significant multi-year contract with the Georgia Department of Transportation valued at a minimum of $50 million, marking a major milestone for the company [11] - The company received recognition for its work in South Carolina, where its technology powers a virtual weigh station network, achieving nearly 100% accuracy in overweight truck targeting [11] Company Strategy and Development Direction - Rekor is entering the global deepfake detection market, leveraging its experience in video analytics for government agencies and law enforcement [12] - The company is focusing on a data-as-a-service business model, which is proving to be a major differentiator in the market [13] - Rekor aims to strengthen its Scout business with the appointment of Jennifer Candelaria as General Manager, focusing on market share expansion and revenue growth [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Rekor's future, highlighting the strong performance and momentum built across technology platforms and customer base [5][15] - The company anticipates continued growth driven by the increasing demand for data-as-a-service solutions and operational efficiencies [10][20] Other Important Information - The company has reduced total operating expenses by 24% quarter over quarter, reflecting discipline and cost containment [8] - Rekor is actively engaged with customers in Europe and plans to expand its business outside the U.S. in 2026 [52] Q&A Session Summary Question: What type of product does the Rekor team envision developing with the deepfake detection division? - Management indicated that the product is being developed by Rekor Labs, and more details will be shared closer to the product launch in 2026 [17][18] Question: How should we think about the EBITDA trajectory and margins over the next several quarters? - Management expects margins to stabilize higher than current levels as the company continues to focus on the data-as-a-service business model [20] Question: Do you see many other contracts similar to the Georgia contract in your pipeline? - Management noted that states often follow each other's procurement processes, and they are seeing unprompted RFPs for their business model [22] Question: Is Austin starting to ramp up with the Command contract? - Management confirmed that Austin has issued a purchase order under the RFP won by Rekor, and they are working to expand into other districts [30][31] Question: Do you expect a full ramp-up portion of the new Georgia contract in the fourth quarter? - Management confirmed that the Georgia contract is in effect since October, and they anticipate billing under the new contract [42] Question: Can you give feedback on the international market engagement? - Management stated that they are actively engaged with customers in Europe and hope to do business outside the U.S. in 2026 [52] Question: Do you believe profitability is what is holding the elevation in the share price? - Management acknowledged the challenges of being a small public company but expressed confidence in the company's ability to drive revenue and profitability [57]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $29.8 million, down from $33.6 million in the same quarter last year, which included a one-time $3 million increase from a licensing agreement [7][8] - Net income rose to $6.9 million from $4.0 million a year ago, and adjusted EBITDA increased to $11.9 million compared to $11.2 million last year [7][8] - Net margin improved to 23.2% and EBITDA margin improved to 39.9%, compared to 11.9% and 33.3% in the same quarter last year [8][9] - The trailing 12-month income from continuing operations was $30.5 million, resulting in earnings per share of $0.64, with a price-to-earnings ratio of over 7.0 times based on a share price of $4.87 [9][10] Business Line Data and Key Metrics Changes - The company faced significant traffic volatility due to algorithmic changes, particularly affecting lifestyle and sports categories, but has seen stabilization and recovery in e-commerce-related content [11][12] - The entrepreneurial publishing model allowed the company to maintain profitability and cash generation despite traffic challenges [12][14] - The company acquired digital assets of ShopHQ and Lindy Sports for $2 million, expanding its e-commerce and sports portfolios [12][13] Market Data and Key Metrics Changes - The company reported that its brands, including Parade, Athlon Sports, TheStreet, and Men's Journal, collectively reach over 100 million users per month [12] - The company is registering over 40,000 new users daily, indicating a strong growth in audience engagement [13][14] Company Strategy and Development Direction - The company is focused on a disciplined M&A strategy, targeting at least one high-value acquisition per quarter to enhance its IP and brand ecosystem [12][13] - The entrepreneurial publishing model is expected to expand into video and social commerce opportunities, leveraging data and AI to build higher-margin revenue streams [13][14] - The company aims to connect user behavior and data across various platforms to enhance monetization opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing industry-wide traffic headwinds but expressed confidence in the company's ability to adapt and maintain profitability [5][11] - The company is optimistic about growth in e-commerce content and expects stabilization and potential growth in news-related content [18][19] - Management emphasized the importance of generating cash and profits, focusing on long-term value creation rather than short-term expediency [24][48] Other Important Information - The company generated $12.1 million in cash from operations during Q3 and reduced total debt by over $10 million year-to-date, strengthening its liquidity position [10] - The company is actively pursuing refinancing options for its outstanding debt, aiming for favorable terms to enhance shareholder value [24] Q&A Session Summary Question: How has the company managed through algorithmic changes and what is the outlook for Q4? - Management noted that they have focused on optimizing content signals and technical SEO, leading to stabilization and expected growth in e-commerce content [18][19] Question: Has the company taken market share during this period of volatility? - Management believes they have weathered the storm better than most competitors and continue to generate cash, indicating a strong position relative to the industry [20] Question: What is the company's approach to refinancing and share repurchase? - Management stated that refinancing is a priority, approached from a position of strength, and they intend to repurchase shares when capital allows and the stock is undervalued [23][39] Question: Can you elaborate on the ShopHQ acquisition and its business model? - Management explained that ShopHQ operates on a drop-shipping model, leveraging valuable data and email lists to drive sales without holding inventory [30][34] Question: What metrics does the company use to measure success in converting content consumers to commerce buyers? - Management focuses on customer acquisition costs and the ability to translate media properties into commerce opportunities, emphasizing cash generation and profitability [48]

Financial Data and Key Metrics Changes - In Q3 2025, revenue was $16.5 million from 130 units shipped, down from $18.4 million from 135 units in the previous quarter, but up from $15.8 million from 94 units a year ago [18] - GAAP gross margin was 15.3%, an increase from 8.8% in Q2 2025 but a decrease from 18.1% in Q3 2024 [19] - Operating loss for the quarter was $7 million, the lowest since going public, down from $7.1 million in Q2 2025 and $9.7 million in Q3 2024 [20] - Non-GAAP operating loss was $4.8 million, also a record low, compared to $6.9 million in Q2 2025 and $6.6 million in Q3 2024 [21] Business Line Data and Key Metrics Changes - The company shipped 130 vehicles in Q3 2025, including 10 strip chassis for a major customer program, with revenue from these expected in future quarters [5] - The company delivered 18 powertrain systems to Bluebird Corporation in Q3 2025, with nearly 80 additional powertrain orders received since the quarter-end [9][10] Market Data and Key Metrics Changes - The company noted strong demand from major customers like UPS and FedEx ISPs, indicating a growing scale and returning customer confidence [5] - The Xos Hub, a mobile energy platform, is gaining traction in various segments, including electric trucks and school buses, with deployments accelerating in Q3 2025 [11] Company Strategy and Development Direction - The company is expanding into higher-margin, lower-concentration categories, including powertrains and energy infrastructure, to diversify its product offerings [9] - The focus is on building deeper relationships with customers and larger programs to create repeatable volume, which is seen as foundational for long-term growth [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to improve margins over time as production scales and cost reduction initiatives are executed [20] - The company anticipates significant opportunities in 2026, with expectations of increased order sizes and a growing product pipeline [12] Other Important Information - The company amended its $20 million convertible note to enhance liquidity, allowing for quarterly principal payments starting in Q4 2025 [23] - Positive free cash flow of $3.1 million was generated in Q3 2025, marking the third time the company has been free cash flow positive since going public [24] Q&A Session Summary Question: What is the expanded opportunity for the hub platform? - Management expects double-digit growth in the EV charging segment, with significant opportunities in power resiliency and backup power applications [30][32] Question: Can you discuss the accelerated growth in chassis deliveries to Bluebird? - The partnership with Bluebird is strengthening, with positive customer feedback and additional orders expected as new powertrain configurations are developed [33][35] Question: What are the expectations for unit deliveries in Q4? - Seasonal delays are anticipated in Q4 due to peak delivery volumes for major customers, but the company expects to remain within its guidance range [36] Question: How is the company managing tariff impacts? - A multi-step approach is being taken to mitigate tariff volatility, including reshoring and working closely with suppliers and customers to share costs [43][45] Question: What are the expectations for margin improvement in 2026? - While specific guidance for 2026 has not been provided, management believes there will be a noticeable improvement in margins due to a favorable mix shift towards higher-margin products [59][61]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenue of $5.3 million, an increase of 87% from $2.8 million in Q3 2024 [4] - Gross margin improved to 74.3% in Q3 2025 from 63.1% in Q3 2024 [5] - The net loss for Q3 2025 was $8 million, or $0.26 per share, down from a net loss of $9.4 million, or $0.38 per share, in the same period last year [5] Business Line Data and Key Metrics Changes - Recurring revenue accounted for $4.1 million, while one-time sales of capital equipment contributed $1.2 million to total revenue [4] - The pilot launch of the new TULSA AI Volume Reduction Software has led to an increase in BPH procedures from Q2 to Q3 and into the first half of Q4 [11] Market Data and Key Metrics Changes - The company has established 70 TULSA-PRO sites, with a growing sales pipeline of 93 new systems in the final stages of the sales process [15] - The TULSA-PRO platform is seeing broader adoption across both academic and community hospitals due to increased awareness of its clinical benefits [15] Company Strategy and Development Direction - The company aims to achieve profitable growth by focusing on existing MR installations and targeting an install base of 200 TULSA-PRO sites [19][21] - Strategic partnerships are being built globally, including distribution agreements in Saudi Arabia and Australia [17] - The introduction of the TULSA AI Volume Reduction Software is expected to significantly enhance the efficiency of BPH treatments, potentially adding 400,000 patients to the annual total addressable market [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to sustain growth, driven by the expanding interest in image-guided interventions and the flexibility of the TULSA system [16] - The company anticipates securing national or regional coverage decisions from commercial payers starting mid-next year, supported by ample clinical data [22] Other Important Information - The Kapton trial has been fully recruited, marking a significant milestone for the company, with data readouts expected to demonstrate TULSA's superiority over robotic surgery [13] - The company plans to file an S3 registration statement to keep financing options open as it moves forward with financial growth [6] Q&A Session Summary Question: Utilization trends in Q3 and Q4 - Management confirmed that the utilization trend has continued into Q4, driven by Medicare reimbursement and individual wins with private insurance [30][31] Question: Commercial payer rates compared to Medicare - Medicare rates are around $13,000, while commercial payer rates range from $25,000 to $65,000 per patient, indicating a significant contribution margin [35][36] Question: Expectations for fourth quarter revenue growth - Management remains comfortable with the 70% growth target for the year, supported by a strong pipeline and recent site closures [45] Question: Closing rates in the sales pipeline - The closing rate for the final stages of the pipeline is expected to be around 50%+, with potential increases as the sales team gains more experience [48] Question: Upcoming data reveals and their impact - The most impactful data reveals will likely be related to clinical efficacy and reimbursement coverage, which are crucial for driving adoption [54][56] Question: Renewed focus on Sonalleve technology - The renewed focus on Sonalleve is driven by recent market interest and the potential for MR-based treatments for various diseases, including uterine conditions and cancers [59][60]